The Thalidomide Controversy: Safety Battles and Corporate Deceit

This chapter examines the timeline of thalidomide's market introduction in 1957, highlighting the serious side effects that emerged, such as birth deformities and nerve damage. It also discusses Grunenthal's questionable tactics to promote the drug and celebrates an FDA official's commitment to ensuring safety amid commercial pressure.